MiR-489 inhibited the development of gastric cancer via regulating HDAC7 and PI3K/AKT pathway

Haiyan Zhang1†, Lingyun Li2†, Cuicui Yuan3, Congcong Wang4, Tiantian Gao5 and Zhiwei Zheng6*

Abstract

Background: Mounting evidences have displayed that the dysregulation of miRNAs plays important roles in the pathogenesis of gastric cancer (GC). The purpose of this study was to explore the biological functions and potential mechanism of miR-489 in GC progression.

Methods: Quantitative real-time PCR (qRT-PCR) and western blot were performed to examine the mRNA expression and protein levels of miR-489 and HDAC7. The relationship between miR-489 and HDAC7 was analyzed by Spearman rank correlation. 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT) assay and transwell assays were conducted for determining the effect of miR-489 and HDAC7 on GC cell viability, migration, and invasion. TargetScan and luciferase reporter assay were used to confirm the target gene of miR-489 in GC cells.

Results: The findings showed that miR-489 was dramatically decreased in GC tissues and GC cell lines (SGC-7901 and MKN45). Moreover, it was closely correlated with overall survival (OS) and progression-free survival (PFS) of GC patients. Downregulation of miR-489 significantly promoted GC cell proliferation, invasion, and migration. Additionally, HDAC7 was confirmed as the direct target of miR-489. Knockdown of HDAC7 exerted inhibited effect on GC progression and it markedly overturned miR-489 inhibitor-mediated effect on GC cells. More interestingly, via targeting HDAC7, miR-489 blocked the activation of PI3K/AKT pathway in GC cells.

Conclusions: Correctively, miR-489 played as a tumor suppressor in GC cell growth by targeting HDAC7, and miR-489 might function as a novel biomarker for diagnosis or therapeutic targets of human GC.

Keywords: Gastric cancer, miR-489, HDAC7, PI3K/AKT pathway

Background

Gastric cancer (GC) is the fourth of the most common malignant tumor in the world and the second leading cause of cancer-related human mortalities [1]. Presently, although the standard therapeutic treatments for GC including surgery, chemotherapy, and targeted therapy are effective, the long-term survival rate is still not ideal [2]. Due to the uncontrollable proliferation and metastasis of tumor cells, the prognosis of GC patients is very poor, so identification of novel and more efficient biomarkers for GC is extremely valuable [3].

MicroRNAs (miRNAs), 19 to 25 nucleotide non-coding RNA molecules, have shown can regulate the expression of various genes which involved in the carcinogenesis, metastasis, invasion, and recurrence of GC [4, 5]. MiRNAs are reported that they can modulate gene expression via binding to mRNAs 3’UTR, resulting in mRNA degradation or blocking mRNA translation. By targeting miRNA, multiple signaling pathways could be modulated by miRNAs, thereby participating in various cellular activities,
including cell survival, differentiation, metastasis, and apoptosis [6, 7]. Growing evidences showed that miRNAs were involved in GC development as tumor suppressors or oncogenes. For example, miR-567 was downregulated in GC tissues and cell lines, miR-567 overexpression inhibited GC tumor growth through PIK3AP1-PI3K/AKT signaling pathway [8]. Wang J et al. found that miR-1224 upregulation suppressed GC metastasis via targeting FAK [9]. However, downregulation of miR-21 inhibited the growth and metastasis of GC cells, which may be a promotion effect on GC progression [10]. MiR-489 was proved to participate in the tumorigenesis of breast cancer, colorectal cancer, and glioma [11–13]. Moreover, Zhang B et al. displayed that miR-489 functions as a tumor suppressor in GC tumor growth and invasion [14]. Nevertheless, miR-489’s mechanism in the modulation of GC viability, migration, and invasion needs further investigation.

In our study, we found a lower expression of miR-489 in GC tissues and cells than that in the control groups. Moreover, upregulating miR-489 inhibited GC cell viability, invasion, and migration. In addition, HDAC7 was determined as the direct target of miR-489. Via targeting HDAC7, miR-489 overexpression suppressed PI3K/AKT pathway in GC cells. In summary, these findings provided the mechanism by which miR-489 regulated GC development.

Materials and methods

Clinical tissues

The fifty-two GC tissues along with matched surrounding normal gastric epithelial tissue samples applied in this study were obtained from People’s Hospital of Rizhao. Informed written consent was obtained from all of the patients. None of them have ever received any types of anti-cancer treatments. This study was approved by the Ethics Committee of People’s Hospital of Rizhao (no. 2014-07-0012). All GC tissues were stored in liquid nitrogen before further analysis.

Cell lines and transfection

Two GC cell lines (SGC-7901 and MKN45) and the normal gastric epithelial cell line (GES-1) were maintained in RPMI-1640 medium containing with 10% FBS, and then cultured in an incubator with an atmosphere of 5% CO₂ at 37 °C.

The miR-489 mimic/inhibitor, HDAC7 siRNA, and their corresponding negative controls were purchased from GeneCopoeia™ (Guangzhou, China). The transfection was conducted by using Lipofectamine 2000 Reagent (Invitrogen, USA).

---

**Fig. 1** Reduce expression of miR-489 in GC is associated with poor prognosis. **a** Decreased of miR-489 in GC tissues (n = 52) was measured by qRT-PCR. **b** miR-489 expression was assessed by qRT-PCR in gastric cancer cell lines SGC7901, MKN45, and immortal gastric epithelial cells (GES-1). **c** Kaplan-Meier curve for overall survival and progression-free survival of GC patients with high or low expression of miR-489. *P < 0.05, **P < 0.01
RT-PCR
Total RNA was isolated from GC tissues and cells via TRIzol reagent. The synthesis of cDNA was performed using M-MLV Reverse Transcriptase Kit. RT-PCR was performed using SYBR Green Real-Time PCR Assay Kit. U6 and GAPDH were served as internal control, and relative expression was calculated using 2-ΔΔCt method. The primer sequences used in this study were as follows:

- **miR-489-F**: 5′-ACACTCCAGCTGGGGTGACATC-3′
- **miR-489-R**: 5′-TGGTGTCGGTGGAGTCC-3′
- **U6-F**: 5′-AGGGTGTCGGTGGAGTCC-3′
- **U6-R**: 5′-AGGGTCCGAGGTATTC-3′
- **HDAC7-F**: 5′-AGGAGCAAGAACTTCGGCAA-3′
- **HDAC7-R**: 5′-CACTGGGGTCCTGGTAGAAA-3′
- **GAPDH-F**: 5′-AGTGTGACGTGATCCGT-3′
- **GAPDH-R**: 5′-GCAGCTCAGTACAGTCCGC-3′

MTT assay
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was performed to examine GC cell viability. GC cells and RPMI-1640 medium were seeded into 48-well plates at a density of 5 × 10^3 cells/well and incubated for 24 h, 48 h, 72 h, and 96 h at 37 °C with 5% CO_2. Then, MTT solution was added to incubate for another 4 h. Finally, enzyme-linked immunosassay was applied for measuring the absorbance at the OD 490 nm using the Multiskan Plate Reader (Thermo Fisher Scientific, Inc.).

Transwell invasion and migration assay
The capacity of GC cells’ invasion and migration treated with miR-489 mimic, or inhibitor was detected with Transwell chambers (8 μm pore diameter, Corning, USA). Cells were put into the upper chamber of the plate at a density of 1 × 10^5 cells/well and incubated for 24 h, 48 h, 72 h, and 96 h at 37 °C with 5% CO_2. Then, MTT solution was added to incubate for another 4 h. Finally, enzyme-linked immunosassay was applied for measuring the absorbance at the OD 490 nm using the Multiskan Plate Reader (Thermo Fisher Scientific, Inc.).

Western blot assay
We isolated the total protein samples from the cultured cells using RIPA lysis buffer supplemented with protease inhibitor (Beyotime). The concentration of the extracted protein was analyzed using BCA kit (Beyotime). The whole protein samples from cell lysates were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis system including 8–15% separation gel and 5% stacking gel, followed by electrotransferred to nitrocellulose membranes (PALL, New York, USA). After blocking with 5% skimmed milk powder for 2 h, the primary antibodies and secondary antibodies were added and incubated overnight at 4 °C and for 2 h, respectively. Finally, the enhanced chemiluminescence detection system was applied for the visual analysis. GAPDH was used as an internal control for the standardization of the proteins.

Dual-luciferase assay
Bioinformatic analysis algorithm TargetScan (https://www.targetscan.org/vert_72/) was used to predict the targets of miR-489. Wild the binding region of HDAC7 was inserted into the pMIR-REPORT luciferase vector, named pMIR-HDAC7-wild. Mutated the binding site of HDAC7 in 3′UTR and cloned into the plasmid, named pMIR-HDAC7-mutant. MiR-489 mimic, miR-489 inhibitor, control mimic/control inhibitor, and luciferase plasmid pMIR-HDAC7 (wild-type/mutant, WT/MuT) were transfected into GC cells by using Lipofectamine 3000 (Invitrogen, CA). After cultivated 48 h, the luciferase activities were detected by Dual-Luciferase Reporter Assay System (Promega Corporation).

| Table 1 | Clinicopathological variables and the expression of miR-489 in gastric cancer patients |
|---------|---------------------------------|
| Item    | Cases | miR-489 | P value |
|---------|-------|---------|---------|
| Age (years) |       |         | 0.790   |
| ≥ 60    | 20    | 8       | 12      |
| < 60    | 32    | 14      | 18      |
| Gender  |       |         | 0.575   |
| Male    | 33    | 13      | 20      |
| Female  | 19    | 9       | 10      |
| TNM stage |       |         | 0.0008**|
| I–II    | 17    | 6       | 11      |
| III–IV  | 35    | 16      | 19      |
| Tumor size |       |         | 0.049*  |
| < 4 cm  | 16    | 10      | 6       |
| ≥ 4 cm  | 36    | 12      | 24      |
| Lymph node metastasis |       |         | 0.746   |
| Yes    | 25    | 10      | 15      |
| No     | 27    | 12      | 15      |
| Distant metastasis |       |         | 0.947   |
| Yes    | 21    | 9       | 12      |
| No     | 31    | 13      | 18      |
| Differentiation |       |         | 0.024*  |
| Low    | 37    | 12      | 25      |
| Well   | 15    | 10      | 5       |
Statistical analysis
The values were represented as the mean ± SD of three times in every experiment. Data were analyzed by the SPSS 22.0 statistical software and the statistics were performed by GraphPad Prism 6. Student’s t test was applied for comparing the difference between two groups. One-way analysis of variance (ANOVA) followed by Tukey’s test was carried out for multiple groups. Pearson’s correlation coefficient was applied for determining the correlation between miR-489 and HDAC7. Log-rank test was applied for analyzing the survival rate. A $P < 0.05$ was considered as statistically significant.

Results
MiR-489 was downregulated in GC tissues and cell lines
RT-PCR was applied for measuring miR-489 expression in 52 paired GC tissues and cell lines. The findings displayed that miR-489 expression in GC tissues was observably lower than normal tissues (Fig. 1a). Additionally, our results show that miR-489 level is reduced in all two GC cell lines compared with that in GES-1 cells (Fig. 1b). Next, miR-489’s clinical significance was investigated in GC patients. High or low expression of miR-489 in GC patients was divided by the median expression of miR-489. We found that miR-489 was closely associated with tumor size...
and differentiation (Table 1). Especially, results of Kaplan-Meier analysis revealed that low expression of miR-489 exhibited a poorer overall survival and progression-free survival of GC patients than those with high expression of miR-489 (Fig. 1c). These data indicated that miR-489 might be an indicator for the prognosis of GC patients.

MiR-489 overexpression suppressed GC cell viability, invasion, and migration.

RT-PCR was applied for measuring miR-489 expression in GC cells after treated with miR-489 mimic or inhibitor. As Fig. 2 a presented, miR-489 expression was obviously increased by miR-489 mimic, while decreased by miR-489 inhibitor in GC cells. MTT assay was applied for determining the effect of miR-489 on GC cell viability. The findings revealed that the cell viability was suppressed by miR-489 overexpression, but promoted by miR-489 silencing in GC cells (Fig. 2b, c). Transwell assays were applied for detecting miR-489 effect on GC cell invasion and migration. Results displayed that overexpression of miR-489 inhibited the migration of GC cells, whereas silencing of miR-489 enhanced cell migration (Fig. 2d). Moreover, miR-489 presented the similar effect on GC cell invasion (Fig. 2e). The above findings suggested that miR-489 overexpression showed inhibitory effect on GC development.

HDAC7 was the direct target of miR-489

The microRNA prediction website http://www.targetscan.org (TargetScan) was performed to predict the possible targets of miR-489. As we saw in Fig. 3 a, the results showed that the 3'UTR region of HDAC7 provided a binding site for miR-489. Subsequently, luciferase reporter assay was applied for further confirming the regulatory relationship between miR-489 and HDAC7. As Fig. 3 b displayed, miR-489 mimic significantly reduced, while miR-489 inhibitor obviously raised the
luciferase activity of HDAC7-3’UTR-WT. However, when combined with HDAC7-3’UTR-MuT reporter, there was no significant change in luciferase activity. Next, RT-PCR and western blot was used for examining HDAC7 level affected by miR-489. As Fig. 3 c and d presented, HDAC7 mRNA and protein level were decreased by miR-489 overexpression, while elevated by miR-489 silencing in GC cells. More importantly, miR-489 expression was negatively related to HDAC7 expression detecting by Pearson’s correlation coefficient (Fig. 3e). The value indicated that HDAC7 was the direct target of miR-489 in GC.

HDAC7 was over-expressed in GC tissues

RT-PCR and western blotting were applied for measuring HDAC7 expression in 52 pairs of GC tissues. Results displayed that HDAC7 mRNA level was observably higher in GC tissues compared to that in normal tissues (Fig. 4a). The similar results were observed in Fig. 4 b. Next, GC patients with high or low expression of HDAC7 were divided by the median expression of HDAC7. Kaplan-Meier analysis revealed that GC patients with high HDAC7 expression showed a poorer survival time than that with low HDAC7 expression (Fig. 4c). The findings demonstrated that HDAC7 might play critical role in GC development.

HDAC7 reversed miR-489 effect on GC development

GC cells were treated with HDAC7 siRNA, miR-489 inhibitor, or miR-489 inhibitor combined with HDAC7 siRNA to investigate HDAC7 effect on miR-489 in the regulation of GC development. As Fig. 5 a shown, HDAC7 level was decreased when the GC cells were treated with HDAC7 siRNA. MTT assay results showed that downregulation of HDAC7 decreased GC cell viability, while miR-489 downregulation increased cell viability. Moreover, HDAC7 siRNA could attenuate miR-489 inhibitor effect on GC cell proliferation (Fig. 5b, c). Transwell migration analysis results showed that decreasing HDAC7 suppressed GC cell migration, and knockdown of miR-489 and HDAC7 in GC cells showed an obviously decreased cell migration compared with knockdown of miR-489 alone (Fig. 5d). The findings of transwell invasion assay were similar to cell migration experiments. MiR-489 inhibitor exerted promoted effect, while HDAC7 siRNA showed suppressed effect on GC cell invasion. Moreover, HDAC7 could attenuate miR-489 effect on cell invasion (Fig. 5e). Collectively, HDAC7 displayed an opposite effect of miR-489 on GC development.

MiR-489/HDAC7 axis regulated EMT and PI3K/AKT pathway in GC cells

HDAC7 was found to activate PI3K/AKT pathway in multiple tumors’ development. Here, we investigated the
effect of miR-489 on EMT and PI3K/AKT pathway in GC cells. The levels of EMT-related markers and the downstream genes of PI3K/AKT pathway were measured by western blot. As we saw in Fig. 6 a, overexpression of miR-489 facilitated the level of E-cadherin, while inhibited N-cadherin and Vimentin levels in GC cells. However, downregulation of miR-489 showed the opposite effect on EMT-related markers. Moreover, knockdown of HDAC7 expression overturned the effect of miR-489 inhibitor on EMT. Additionally, miR-489 upregulation inhibited, miR-489 downregulation facilitated, and combined with HDAC7 downregulation attenuated the downstream genes of PI3K/AKT pathway, including p-P13K, P13K, and p-AKT, AKT (Fig. 6b). These data indicated that miR-489 inhibited GC development through PI3K/AKT pathway by targeting HDAC7.

**Discussion**

Gastric cancer is a serious threat to human health. Currently, the incidence of gastric cancer is the fourth highest in the world, and it has the second highest mortality rate [15]. First choice in the treatment of gastric cancer is surgery [16], but because of early gastric cancer clinical manifestation is not obvious, medical screening...
mechanism is imperfect, diagnosis of gastric cancer rate is low in our country, terminal patients are likely to lose operation time or miss the optimal timing of surgery [17]. Accumulating evidences have displayed that the dysregulation of miRNAs served key roles in tumors’ development [18–20]. In this study, results showed a decreased miR-489 in GC tissues and cells and miR-489 served as an indicator for the prognosis of GC patients. Moreover, miR-489 inhibitor displayed facilitating effect on GC development. Additionally, HDAC7 acted as a direct target of miR-489. More importantly, PI3K/AKT pathway was modulated by miR-489/HDAC7 axis in GC cells.

MiR-489 was proved to take part in a variety of tumors’ development as a tumor suppressor. For instance, miR-489 re-expression suppressed the tumorigenesis of breast cancer [21]. Moreover, Gao S et al. displayed that miR-489 repressed tumor growth and the invasion of colorectal cancer [12]. Also, miR-489 showed the suppression effect on glioma cell proliferation and facilitating effect on cell apoptosis [13]. Here, in this study, we displayed that miR-489 showed an inhibitory effect on GC development as well. Restoration of miR-489 repressed GC cell viability, invasion, and migration, while knockdown of miR-489 facilitated GC progression.

Currently, the molecular mechanism of miR-489 in the regulation of GC development is not fully understood. TargetScan database was applied for predicting miR-489’s target gene and the results showed that HDAC7 was one of the candidate target genes of miR-489. Histone deacetylase HDAC7 is proved to be involved in a variety of cellular physiological processes and as a novel target for tumor therapy [22–24]. Previous studies have showed that HDAC7 was involved in the malignant phenotype of glioma regulated by ZNF326 [25]. Sang Y et al. displayed that HDAC7 facilitated cell growth and metastasis of lung cancer [26]. Moreover, Peixoto P et al. found that inhibiting HDAC7 reduced the tumorigenic activity of human glioblastoma and provided a new opportunity for tumor treatment [27]. Yu Y et al. have shown that high HDAC7 expression in cancerous gastric tissues correlates with distant metastasis and predicts a poor prognosis for patients with gastric cancer [28]. However, the
regulatory effect of HDAC on GC has not been elucidated to a large extent. In this study, we revealed that HDAC was increased obviously in GC tissues and cells and displayed the opposite effect of miR-489 on GC development. More importantly, knockdown of HDAC7 overturned miR-489 inhibitor effect on facilitating GC cell viability, invasion, and migration.

The activation of PI3K/AKT pathway has been reported to take part in tumor cell proliferation and apoptosis [29–31]. Here, we proved that knockdown of miR-489 promoted the activation of PI3K/AKT signaling pathway and miR-489 restoration showed the opposite effect.

**Conclusion**

All in all, miR-489 expression was decreased in GC while HDAC7 was increased and overexpression of miR-489 suppressed GC cell viability, invasion, and migration. HDAC7 was a target of miR-489 in regulating GC progression and miR-489 achieved the suppressed effect on GC by regulating PI3K/AKT signaling pathway.

**Acknowledgements**

Not applicable.

**Authors’ contributions**

HZ and LL contributed to the conception of the study. CY and CW contributed significantly to the data analysis and study preparation. TG and ZZ performed the data analyses and wrote the study. HZ helped perform the analysis with constructive discussions. All authors have read and approved the final study.

**Funding**

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

**Availability of data and materials**

The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.

**Ethics approval and consent to participate**

Approval for the study was obtained from the Ethics Committee of People’s Hospital of Rizhao. Informed consent was obtained from all the patients whose tissues were used in this study.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1. Department of Gastroenterology, People’s Hospital of Rizhao, Rizhao 276800, China.
2. Department of Internal Medicine, Laishan Branch Hospital of Yantai Yuhuangding Hospital, Yantai 264003, China.
3. Department of Cardiovascular Medicine, The People’s Hospital of zhangqiu area, Jinan 250200, China.
4. Department of Operation Room, The People’s Hospital of zhangqiu area, Jinan 250200, China.
5. Department of Nephrology, The People’s Hospital of zhangqiu area, Jinan 250200, China.
6. Department of General Surgery, People’s Hospital of Rizhao, 126, Tai’an Road, Rizhao 276800, China.

**Received: 8 January 2020 Accepted: 30 March 2020**

**References**

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.
2. Wadhwa R, Song S, Lee JS, Yao Y, Wei Q, Ajani JA. Gastric cancer-molecular and clinical dimensions. Nat Rev Clin Oncol. 2013;10:643–55.
3. Veronese N, Fassan M, Wood LD, Stubbs B, Solmi M, Capelli P, P ea A, Nottegar A, Sergi G, Manzato E, et al. Extranodal extension of nodal metastases is a poor prognostic indicator in gastric cancer: a systematic review and meta-analysis. J Gastrointest Surg. 2016;20:1692–8.
4. Yun Z, Tan Y, Wang Y, Ding W, Chu Y, Xu J, Jiang R, Xu X. Hypoxia decreases macrophage glycolysis and M1 percentage by targeting miR-30c and mTOR in human gastric cancer. Cancer Sci. 2019;110(8):2368–77.
5. Liu X, Lu Y, Xu Y, Hou S, Huang J, Wang B, Zhao J, Xia S, Fan S, Yu X, et al. Exosomal transfer of miR-501 confers doxorubicin resistance and tumorigenesis via targeting of BLID in gastric cancer. Cancer Lett. 2019;459:122–34.
6. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.
7. Lin S, Gregory RI. MicroRNA biogenesis pathways in cancer. Nat Rev Cancer. 2015;15:321–33.
8. Zhang F, Li K, Yao X, Wang H, Li W, Wu J, Li M, Zhou R, Xu L, Zhao L. A miR-567-PK3AP1-PI3K/AKT-c-Myc feedback loop regulates tumour growth and chemo resistance in gastric cancer. EbioMedicine. 2019;49:311–21.
9. Wang J, Wen T, Li Z, Che X, Geng L, Yang X, Zhang J, Tang H, He L, Xu Q, Liu Y. MicroRNA-1224 inhibits tumor metastasis in intestinal-type gastric cancer by directly targeting FAK. Front Oncol. 2019;9:222.
10. Yao SS, Han L, Tian ZB, Yu YN, Zhang Q, Li XY, Mao T, Yang L. Celastrol inhibits growth and metastasis of human gastric cancer cell MKN45 by down-regulating microRNA-21. Phytother Res. 2019;33(9):1706–16.
11. Patel Y, Soni M, Awuglewitsch A, Kern MJ, Liu S, Shah N, Singh UP, Chen H. Overexpression of miR-489 derails mammary hierarchy structure and inhibits HER2/neu-induced tumorigenesis. Oncogene. 2019;38:445–53.
12. Gao S, Liu H, Hou S, Wu L, Yang Z, Shen J, Zhou L, Zheng SS, Jiang B. miR-489 suppresses tumor growth and invasion by targeting HDAC7 in colorectal cancer. Clin Transl Oncol. 2018;20:703–12.
13. Li Y, Ma X, Wang Y, Li G: miR-489 inhibits proliferation, cell cycle progression and induces apoptosis of glioma cells via targeting SPIN1-mediated PI3K/AKT pathway. Biomed Pharmacother. 2017;93:43–45.
14. Zhang B, Ji S, Ma F, Ma Q, Lu X, Chen X: miR-489 acts as a tumor suppressor in human gastric cancer by directly targeting FAK. Am J Cancer Res. 2016;6:2021–30.
15. Son T, Hyung WJ. Laparoscopic gastric cancer surgery: current evidence and future perspectives. World J Gastroenterol. 2016;22:727–35.
16. Lee JH, Kim JK, Jung HK, Kim JH, Jeong WK, Jeon TJ, Kim JM, Kim YI, Ryu KW, Kong SH, et al. Clinical practice guidelines for gastric cancer in Korea: an evidence-based approach. J Gastric Cancer. 2014;1487–104.
17. Son T, Kwon KG, Hyung WJ. Minimally invasive surgery for gastric cancer treatment: current status and future perspectives. Gut Liver. 2014;8:229–36.
18. Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017;16:203–22.
19. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6:587–60.
24. Ahn MY, Yoon JH. Histone deacetylase 7 silencing induces apoptosis and autophagy in salivary mucoepidermoid carcinoma cells. J Oral Pathol Med. 2017;46:276–83.

25. Yu X, Wang M, Wu J, Han Q, Zhang X. ZNF326 promotes malignant phenotype of glioma by up-regulating HDAC7 expression and activating Wnt pathway. J Exp Clin Cancer Res. 2019;38:40.

26. Sang Y, Sun L, Wu Y, Yuan W, Liu Y, Li SW. Histone deacetylase 7 inhibits plakoglobin expression to promote lung cancer cell growth and metastasis. Int J Oncol. 2019;54:1112–22.

27. Peixoto P, Blomme A, Costanza B, Ronca R, Rezzola S, Palacios AP, Schoysman L, Bouthy S, Goffart N, Peelen O, et al. HDAC7 inhibition resets STAT3 tumorigenic activity in human glioblastoma independently of EGFR and PTEN; new opportunities for selected targeted therapies. Oncogene. 2016;35:4481–94.

28. Yu Y, Gao F, Yu X, Zhou P, Di Q, Lei J, Tai Y, Wu H, Li X, Wang X, et al. The expression of HDAC7 in cancerous gastric tissues is positively associated with distant metastasis and poor patient prognosis. Clin Transl Oncol. 2017;19:1045–54.

29. Gao X, Qin T, Mao J, Zhang J, Fan S, Lu Y, Sun Z, Zhang Q, Song B, Li L. PTEN1/miR-20a/PTEN axis contributes to breast cancer progression by regulating PTEN via PI3K/Akt pathway. J Exp Clin Cancer Res. 2019;38:256.

30. Ippen FM, Grosch JK, Subramanian M, Kuter BM, Liederer BM, Plise EG, Mora JL, Nayyar N, Schmidt SP, Gobbie-Hurder A, et al. Targeting the PI3K/Akt/mTOR-pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastases. Neuro Oncol. 2019;21(11):1401–11.

31. Yang HL, Thiyagarajan V, Shen PC, Mathew DC, Lin KY, Liao JW, Hseu YC. Anti-EMT properties of CoQ0 attributed to PI3K/AKT/NFKB/MMP-9 signaling pathway through ROS-mediated apoptosis. J Exp Clin Cancer Res. 2019;38:186.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.